The aim of this feasibility, prospective, single-center trial is to compare an intra-oral Photobiomodulation (PBM) via the Caremin650TM device (NeoMedLight) and a transcutaneous PBM via the ATP 38® device (Swiss Bio Innov) in patients treated with radiotherapy or chemoradiotherapy for cancer of the oropharynx or oral cavity. PBM session will be carried out first at the rate of two sessions per week for preventive purposes, and then, in case of occurence of grade 1 mucositis, three sessions per week with curative purpose.
Adult patient (18 years old and older);
Patients with oral cavity or oropharynx cancer treated with radiotherapy or chemo-radiotherapy;
Karnofsky Performance Status > 60%;
Able to understand French;
Allergy to polyurethanes;
Head and Neck tumors that are localized to other sites than oral cavity or oropharynx
Previous irradiation of Head and Neck (whatever the time lapse between the two irradiations)
Pregnant and breastfeeding woman;